早期过继性免疫治疗主要是将自体口服的肿瘤反应性T细胞输回患者体内,以攻击患者的肿瘤,这个方法已经成功。但该疗法并未得到广泛应用,主要是由于侵袭性淋巴细胞数量少,且不能提高机体自身免疫系统的抗肿瘤能力。T细胞基因工程疗法可以在一定程度上克服T细胞存活率低、迁移率低和免疫逃逸等挑战。从患者的血液中提取T细胞并进...
Clinical Trials as TopicNeoplasmsThe transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit gr...
[5]FDA probes CAR-T therapies' 'serious risk' of secondary cancer [6]Bonaldo G, Montanaro N, AlbertoVaccheri, Motola D. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. Eur J Clin Pharmacol. 2021 Aug;77(8):1225-1234. doi: 10.1007/s00228...
CD19 CAR T cell therapy has emerged as a promising therapy in the treatment of B cell malignancies, such as B cell acute lymphoblastic leukemia (B-ALL). Ho... T Chour,A Hirayama,Y Zheng,... - 《Cancer Research》 被引量: 0发表: 2022年 CAR T-Cell therapies in lymphoma: current lan...
他们在顶级期刊《自然·医学》报道了由CRISPR–Cas9 PD-1编辑的T细胞在晚期非小细胞肺癌患者中进行的首次人类I期临床试验的结果（ClinicalTrials.gov NCT02793856）。论文题为“Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer”。研究人员们得出结论，CRISPR–...
2021年11月,来自美国的医学研究者们发布了一项CAR-T联合PD-1抑制剂的临床试验的I期结果在知名《Cancer Discovery》杂志上,主要阐述了以间皮素为靶点的自体CAR-T细胞与帕博利珠单抗(pembrolizumab,商品名Keytruda)联用治疗恶性胸膜间皮瘤...
Conclusions and RelevanceCAR T-cell therapy is an FDA-approved therapy that has improved progression-free survival for multiple myeloma, improved overall survival for large B-cell lymphoma, and attained high rates of cancer remission for other hematologic malignancies such as acute lymphobl...
T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with three approved products for B-cell malignancies and a large pipeline of treatments in clinical trials. However, there are several challenges to their broad implementation. These include insufficient expansion of...
1.Cancer cell therapies: the clinical trial landscape. Nature Reviews Drug Discovery. 2020. doi: 10.1038/d41573-020-00099-9 2.Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials. Clinical Cancer Research.2020. DOI: 10.1158/1078-043...
[34] DAVIS J L, THEORET M R, ZHENG Z L, et al. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials[J]. Clin Cancer Res, 2010, 16(23): 5852-5861...